Coherus Oncology (CHRS) Assets Average (2014 - 2026)

Coherus Oncology has disclosed Assets Average across 13 years of filings, most recently posting $262.2 million for Q1 2026.

• Assets Average for Q1 2026 came in at $262.2 million, down 36.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $262.2 million (down 36.02% YoY), and the FY2025 annual result was $353.4 million, down 34.44% from the prior year.
• Assets Average came in at $262.2 million for Q1 2026 at Coherus Oncology, down from $387.4 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $719.2 million in Q2 2024 to a low of $262.2 million in Q1 2026.
• The 5-year median for Assets Average is $515.9 million (2022), against an average of $512.2 million.
• Across the five-year window, Assets Average soared 64.95% in 2024 and slumped 43.65% in 2025, its largest moves.
• Coherus Oncology's Assets Average stood at $515.9 million in 2022, then gained by 17.6% to $606.7 million in 2023, then decreased by 21.42% to $476.8 million in 2024, then fell by 18.74% to $387.4 million in 2025, then plunged by 32.33% to $262.2 million in 2026.
• The last three Assets Average figures came in at $262.2 million (Q1 2026), $387.4 million (Q4 2025), and $478.0 million (Q3 2025), per Business Quant data.